Home | Welcome to Contract Pharma   
Last Updated Tuesday, September 2 2014
Print

Search Results for 'Gil Roth'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

By Gil Roth
Published February 26, 2014
Exchange of ideas can lead to mutually beneficial linkages Read More »
Newsmakers: Pfizer Global Manufacturing
By Gil Y. Roth
Published July 9, 2010
Catching up with PGM Senior VP Tony Maddaluna after Pfizer's restructuring plans were revealed Read More »
10th Anniversary: CRO Perspectives
By Gil Y. Roth
Published October 8, 2009
10 Years On: CRO Perspectives By Gil Y. Roth Contract Research Organizations have followed different paths and models over the past decade. We asked several of the major CROs about the biggest changes and trends they've seen in… Read More »
By Gil Roth
Published April 30, 2008
From Heparin to the A350 Read More »
By Gil Y. Roth
Published April 2, 2008
Aseptic Boot Camp By Gil Y. Roth For more than 30 years, the University of Tennessee College of Pharmacy has conducted "A Hands-On Training Program in Aseptic Processing." This 40-hour lecture and lab course "provides a compr… Read More »
Newsmakers: Peter Bigelow
By Gil Roth
Published January 24, 2011
A conversation with Patheon�s interim CEO Read More »
By Gil Y. Roth
Published October 8, 2009
Amgen and SAFC discuss supply chain safety Read More »
2007 Top 10 Biopharmaceutical Companies Report
By Gil Roth
Published July 19, 2007
Warts and all, Amgen remains at the apex of the Top 10 Biopharma rankings. The first half of 2007 was none too kind to the top gun, but Amgen still has a comfortable lead over its competitors on this list. Read More »
By Gil Roth
Published June 4, 2007
Engineering in India IPS adds Indian office by Gil Y. Roth Integrated Project Services (IPS), an engineering, design/build, validation and compliance company, recently opened two offices in India: Hyderabad and New Delhi. The offices w… Read More »
2006 Top 20 Pharmaceutical Companies Report
Published July 18, 2006
Last year (our 2005 edition), Pfizer was 47% ahead of its closest competitor in drug revenues ($46 billion to $31 billion), but that margin was shaved to 30% in 2005 as Pfizer sales dropped 4%. Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On